Your session is about to expire
← Back to Search
Experimental Medication
DUR-928 30 mg for Alcoholic Hepatitis (AHFIRM Trial)
Phase 2
Waitlist Available
Research Sponsored by Durect
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial is testing DUR-928, a new medication, in people with Alcoholic Hepatitis to see if it can help their liver heal and function better.
Eligible Conditions
- Alcoholic Hepatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2019 Phase 2 trial • 19 Patients • NCT0343226025%
Pruritus generalised
25%
Renal pain
25%
Anemia
25%
Ascites
25%
Nausea
25%
Hyperkalaemia
25%
Blood alkaline phosphatase increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Moderate AH DUR-928 30 mg
Moderate AH DUR-928 90 mg
Severe AH DUR-928 30 mg
Severe AH DUR-928 90 mg
Severe AH DUR-928 150 mg
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: DUR-928 (larsucosterol, 90 mg)Experimental Treatment1 Intervention
Group II: DUR-928 (larsucosterol, 30 mg)Experimental Treatment1 Intervention
Group III: (Placebo) Sterile Water for InjectionPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DUR-928 90 mg
2021
Completed Phase 2
~330
DUR-928 30 mg
2021
Completed Phase 2
~330
Find a Location
Who is running the clinical trial?
DurectLead Sponsor
16 Previous Clinical Trials
1,812 Total Patients Enrolled
CTI Clinical Trial and Consulting ServicesOTHER
35 Previous Clinical Trials
3,483 Total Patients Enrolled
Robert Gordon, MD, FACSStudy DirectorCTI Clinical Trial and Consulting Services
Share this study with friends
Copy Link
Messenger